Company
Headquarters: Mont-Saint-Guibert, Belgium
Employees: 71
CEO: Mr. Olivier Taelman
$193.6 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $201.46 B |
| EssilorLuxottica SA | $144.43 B |
| Becton, Dickinson and Company | $55.63 B |
| HOYA Corp | $50.63 B |
| Alcon Inc. | $39.46 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Nyxoah SA has the following listings and related stock indices.
Stock: NASDAQ: NYXH wb_incandescent
Stock: FSX: 5YI wb_incandescent